The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma (MPM).
Gerard Zalcman
Consultant or Advisory Role - Bristol-Myers Squibb; Lilly; Roche
Julien Mazieres
No relevant relationships to disclose
Arnaud Scherpereel
No relevant relationships to disclose
Jacques Margery
No relevant relationships to disclose
Denis Moro-Sibilot
No relevant relationships to disclose
Jean-Jacques Parienti
No relevant relationships to disclose
Valérie Gounant
No relevant relationships to disclose
Alain Riviere
No relevant relationships to disclose
Isabelle Monnet
No relevant relationships to disclose
Oliver Molinier
No relevant relationships to disclose
Hervé Lena
No relevant relationships to disclose
Sylvie Friard
No relevant relationships to disclose
Jean-Paul Duhamel
No relevant relationships to disclose
Clarisse Audigier-Valette
No relevant relationships to disclose
Gilles Robinet
No relevant relationships to disclose
Christian Creveuil
No relevant relationships to disclose
Catherine Ligeza-poisson
No relevant relationships to disclose
Franck Morin
No relevant relationships to disclose